Close menu




May 25th, 2022 | 10:44 CEST

All eyes on Deutsche Bank and Commerzbank - but Aspermont has the greatest leverage

  • Investments
  • Technology
  • Mining
Photo credits: pixabay.com

The two best-known German banks are currently in demand on the market. Why? The interest rate turnaround means that the typical bread-and-butter business with loans is profitable again. Business picks up when banks have room to manoeuvre with interest rates in positive territory. Also, the increasingly weaker environment for corporate financing at the upper end of the risk scale ensures that banks take on a more critical role as traditional intermediaries. We take a closer look at Commerzbank and Deutsche Bank, but we also have an exciting second-tier stock on our list that could become an insider tip thanks to its unique selling propositions and growth potential.

time to read: 2 minutes | Author: Nico Popp
ISIN: DEUTSCHE BANK AG NA O.N. | DE0005140008 , COMMERZBANK AG | DE000CBK1001 , ASPERMONT LTD | AU000000ASP3

Table of contents:


    Deutsche Bank and Commerzbank: Lagarde is in a good mood

    Deutsche Bank's share price has risen significantly in recent days. However, on a one-year horizon, it still stands at a loss of around 17%. The latest upward trend stems from statements by ECB chief Christine Lagarde, who has held out the prospect of an end to the bond-buying program - in return, interest rates in the eurozone could rise as early as this summer. That is good news for banks: On the one hand, an asset class that had almost been forgotten is coming back to life in the form of bonds, and on the other hand, capital is earning money again.

    Prices beyond EUR 10 are positive for investors; then, the value could go back into an upward trend. However, investors should keep in mind that Deutsche Bank is more of a large tanker than a nimble speedboat. However, there is potential in any case - also with a view to the entire financial sector. Also exciting is the Commerzbank share, where, significantly, Deutsche Bank recently issued a buy recommendation. The reason for the recommendation is the already increased net interest income.

    Aspermont: Financing platform comes at the right time

    Banks and other players in the financial sector need to be aware of the new potential that is emerging. In recent years, large corporations, in particular, have often been driven by short-term profit targets and have positioned themselves leanly. However, once business relationships have fallen asleep, they can no longer be exploited when the sun shines again. The situation is different at Aspermont. The Australian media company, with offices around the globe, publishes Mining Magazine and other venerable publications that are recognized industry journals for the mining sector. What sounds like a somewhat dusty daily newspaper has been digital at Aspermont for many years. It is tailored to the needs of producers, suppliers, and buyers from industry and investors.

    From these long-standing business relationships, Aspermont draws the potential to initiate new business areas effectively. The Company recently announced the Blu Horseshoe platform, allowing investors to participate in rounds of company financing on the Australian Stock Exchange (ASX). The process is digital and transparent, offering investors cost benefits above all. Participating companies benefit because their investor base increases, and the process for investors is greatly simplified. At the same time, the platform aims to democratize direct investments in growth companies - from deals between networks to an open market.


    Aspermont is thus poaching in the territory of brokers and banks. The advantage of this digital business is that it can possibly even be transferred to other markets - growth companies worldwide are looking for capital. High inflation is forcing investors to look for opportunities on the stock market even in economically uncertain times. While traditional banks, such as Commerzbank, invest only to a limited extent in growth projects, at Aspermont, the share of these investments plays a greater role in terms of the expected potential. Investors can see opportunities in this. The Aspermont share currently seems to have found a bottom.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:33 CEST

    Copper Discoveries, AI Chips and Mobile Communications: Power Metallic, Infineon and Deutsche Telekom After the Pullbacks

    • Copper
    • polymetallic deposit
    • Electrification
    • AI
    • Chips
    • Data centres
    • Satellites
    • Technology
    • Telecommunications

    Power Metallic Mines, Infineon and Deutsche Telekom come from very different sectors. On the stock market, however, they currently share the same question: do the pullbacks offer buying opportunities? Following its recent resource estimate, Power Metallic is working on an initial economic assessment. Analysts see significant upside potential in the stock. At chipmaker Infineon, expectations for its AI business are rising, and investors are watching for the next results. At the telecommunications group, concerns about new competition from SpaceX are growing. Where are the greatest opportunities?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read